{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.76","value":"12.77"},{"groupId":"OG001","spread":"0.98","value":"12.50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"description":"-Defined as ANC ≥0.5 x 10\\^9/L for 3 consecutive days or ≥1.0 x 10\\^9/L for 1 day","dispersionType":"Standard Deviation","groups":[{"description":"Patients will receive six doses of Uproleselan intravenously. The doses will begin the evening of Day -3 and continue every 12 hours through the morning of Day 0, prior to hematopoietic stem cell transplant (auto-HCT). On the evening of Day -2, patients also receive one dose of standard of care Melphalan intravenously.","id":"OG000","title":"Uproleselan + Standard of Care Melphalan"},{"description":"Patients will receive six doses of placebo intravenously. The doses will begin the evening of Day -3 and continue every 12 hours through the morning of Day 0, prior to hematopoietic stem cell transplant (auto-HCT). On the evening of Day -2, patients also receive one dose of standard of care Melphalan intravenously.","id":"OG001","title":"Placebo + Standard of Care Melphalan"}],"paramType":"MEAN","populationDescription":"One subject dropped out of Placebo + Standard of Care Melphalan arm due to adverse events and was not included in the analysis for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Through date of discharge (up to be 18 days)","title":"Time to Neutrophil Engraftment","type":"SECONDARY","unitOfMeasure":"Days"}